Innovent climbs as partner Ollin to be acquired by Johnson & Johnson
** Shares of China's Innovent Biologics 1801.HK climb 3.2% to HK$86.55, on track for the biggest one-day pct gain since November 5
** Stock touches the highest level since November 12
** Innovative medicines developer and producer says its partner Ollin Biosciences Inc has entered into agreement to be be acquired by Johnson & Johnson JNJ.N, together with the next-generation medicines for patients with vision-threatening eye diseases
** Ollin's lead program OLN324 was discovered by Innovent and out-licensed to Ollin
** Johnson & Johnson JNJ.N said on Monday it had agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion, expanding its pipeline of eye disease therapies
** YTD, Innovent shares up 12.1%, Hang Seng Biotech Index .HSBIO up 0.6%